Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company was incorporated in 1991 and is based in Uppsala, Sweden.
Metrics to compare | CLBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLBIOPeersSector | |
---|---|---|---|---|
P/E Ratio | −13.0x | 0.0x | −0.5x | |
PEG Ratio | 0.03 | 0.00 | 0.00 | |
Price/Book | 3.8x | 0.0x | 2.6x | |
Price / LTM Sales | 23.0x | 0.0x | 3.3x | |
Upside (Analyst Target) | 41.8% | 0.0% | 43.4% | |
Fair Value Upside | Unlock | 0.0% | 7.1% | Unlock |